Helsinn and Johnson & Johnson returned to add $21m in extra funding to the $44m series B round the surgical marker developer closed in 2018.
The WuXi AppTec-backed infectious disease therapeutics developer has closed a series C round featuring various investment managers and Singapore's sovereign wealth fund.
New and existing investors provided crossover financing for the synthetic biology technology developer, which already counts Merck & Co, AGC Asahi Glass and JSR Life Sciences as investors.
Bayer could exit the drug discovery technology developer should it complete an initial public offering on the Nasdaq Global Select Market.
The Novartis-backed gene therapy developer will merge with Chardan Healthcare Acquisition 2 Corp and take a New York Stock Exchange listing.
Helsinn is co-anchoring the second 3B Future Health Fund, which will target oncology and rare disease therapeutics startups as it seeks a $118m close.
M12 co-led a $22m series A round for the drug discovery technology developer with Playground Global, and both investors have taken board seats.
Cedars-Sinai contributed to a round boosting the virtual reality therapeutics developer's overall funding to $35m.
JSR Life Sciences Corporate Venture Fund will invest in developers of innovative drug research, development or manufacturing technology.
The iFlytek-backed post-discharge care management platform received $23m in a round led by Sequoia Capital China.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
